Product Update:

insulin glargine 300 units/mL solution for injection in a pre-filled pen (Toujeo®)

SMC No. (1078/15)

Sanofi

10 July 2015 (Issued 7 August 2015)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**Insulin glargine (Toujeo®)** is accepted for restricted use within NHS Scotland.

**Indication under review:** Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above.

**SMC restriction:** Its use should be targeted on patients with Type I diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.

Insulin glargine 300 units/mL (Toujeo®) has similar efficacy but is not bioequivalent to insulin glargine 100 units/mL and therefore not interchangeable without dose adjustment. At doses that provide comparable glycaemic control, Toujeo® is available at a similar cost to insulin glargine 100 units/mL.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 12 May 2015.

**Vice Chairman**
Scottish Medicines Consortium

Published 07 September 2015